TARS
Tarsus Pharmaceuticals Inc
75.70$
-0.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1,729.7% | -300.8% | -136.8% | -35.3% | -18.0% | -33.4% | -26.4% | -28.6% | 15.4% | 12.7% | -15.2% | 38.4% | 13.1% | |
| 13.0% | 2.7% | 1.0% | 0.6% | 0.6% | 0.7% | 0.6% | 0.4% | 0.3% | 0.3% | 0.3% | 0.6% | 0.4% | |
| 280.6% | 41.9% | 20.0% | 18.3% | 15.4% | 11.1% | 8.8% | 8.0% | 10.3% | 9.4% | 7.4% | 7.6% | 8.5% | |
| 75.1% | -21.5% | -31.1% | 25.1% | -3.5% | -8.6% | -2.4% | -15.9% | 16.3% | 9.0% | -18.2% | 20.1% | 6.3% | |
| 233.8% | 30.6% | 0.6% | 2.5% | 0.6% | 7.6% | 0.8% | 1.0% | 1.6% | 4.2% | 3.6% | 2.3% | 3.0% | |
| 2,531.7% | 136.5% | -370.2% | -99.3% | 6.5% | -89.7% | -44.6% | -50.4% | -4.0% | 32.5% | -36.1% | 21.8% | 3.9% | |
| – | – | – | -16.4% | 13.9% | – | – | – | – | – | – | – | – | |
| – | – | – | – | 0.0% | 0.0% | – | – | 0.0% | 0.0% | – | – | – | |
| 5,606.3% | 151.1% | 393.9% | 103.7% | 1.3% | 4.4% | 174.3% | 1.9% | 2.2% | 1.5% | 0.7% | 2.0% | 1.6% | |
| 6,408.3% | -13.2% | -113.1% | -30.9% | -10.2% | -118.7% | 103.4% | -77.1% | 13.5% | 46.8% | -50.6% | 62.2% | 18.7% | |
| -1,963.5% | -300.8% | -137.5% | -37.8% | -18.6% | -41.0% | -27.1% | -29.6% | 13.8% | 8.6% | -18.8% | 36.1% | 10.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.